Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer. Adaptive has identified autoreactive or offender TCRs that could…
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact. The article frames the Cartography pact as the second major Pfizer external…
Management: 'This quarter we kicked off our RA Target Discovery partnership with Pfizer.' Adaptive received over 1,000 Pfizer patient samples and is on track…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Pfizer and Adaptive entered two non-exclusive immune receptor licensing agreements. Adaptive will lead target discovery to identify disease-specific RA TCRs; Pfizer responsible for development/commercialization. Total deal up to ~$890M in upfront, data delivery, development, commercial and sales milestones.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Adaptive Biotechnologies Corp. (this deal) | 2025 | $890M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2025 deals · Pfizer Inc. deals · Immunology deals